Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry

Autor: Ian L. McAllister, Socorro Alforja, Samantha Fraser-Bell, Louise O'Toole, Daniel Barthelmes, Jennifer J. Arnold, Martin Guillemin, Javier Zarranz-Ventura, Pierre-Henry Gabrielle, Ricardo P. Casaroli Marano, Hemal Mehta, Vuong Nguyen, Catherine Creuzot-Garcher, Adrian Hunt, Mark C Gillies
Přispěvatelé: University of Zurich, Hunt, Adrian R, Westmead Hospital, The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia, The University of Sydney, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hospital Clínic de Barcelona, Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Marsden Eys Specialists, The University of Western Australia (UWA), Mater Private Hospital, Universitätsspital Zürich (USZ), Sydney Eye Hospital, Moorfields Eye Hospital
Rok vydání: 2020
Předmět:
10018 Ophthalmology Clinic
Vascular Endothelial Growth Factor A
retina
vision
medicine.medical_specialty
Visual acuity
genetic structures
Recombinant Fusion Proteins
2804 Cellular and Molecular Neuroscience
Visual Acuity
Macular oedema
610 Medicine & health
Angiogenesis Inhibitors
Macular Edema
03 medical and health sciences
Cellular and Molecular Neuroscience
2809 Sensory Systems
0302 clinical medicine
Ophthalmology
Ranibizumab
Retinal Vein Occlusion
medicine
Humans
macula
Registries
[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs
Aflibercept
business.industry
Outcome measures
medicine.disease
2731 Ophthalmology
Sensory Systems
3. Good health
Receptors
Vascular Endothelial Growth Factor
030220 oncology & carcinogenesis
Cystoid macular oedema
Intravitreal Injections
030221 ophthalmology & optometry
Mixed effects
Branch retinal vein occlusion
medicine.symptom
business
treatment medical
medicine.drug
Zdroj: British Journal of Ophthalmology
British Journal of Ophthalmology, BMJ Publishing Group, In press, bjophthalmol-2020-318491. ⟨10.1136/bjophthalmol-2020-318491⟩
ISSN: 1468-2079
0007-1161
DOI: 10.1136/bjophthalmol-2020-318491⟩
Popis: Background/AimsTo compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months.MethodsA multicentre, international, database observational study recruited 322 eyes initiating therapy in real-world practice over 5 years. The main outcome measure was mean change in EDTRS letter scores of visual acuity (VA). Secondary outcomes included anatomic outcomes, percentage of eyes with VA >6/12 (70 letters), number of injections and visits, time to first inactivity, switching or non-completion.ResultsGeneralised mixed effect models demonstrated that mean (95% CI) adjusted 12-month VA changes for ranibizumab and aflibercept were similar (+10.8 (8.2 to 13.4) vs +10.9 (8.3 to 13.5) letters, respectively, p=0.59). The mean adjusted change in central subfield thickness (CST) was greater for aflibercept than ranibizumab (−170 (−153 to –187) µm vs −147 (−130 to –164) µm, respectively, p=0.001). The overall median (Q1, Q3) of 7 (4, 8) injections and 9 (7, 11) visits was similar between treatment groups. First grading of inactivity occurred sooner with aflibercept (p=0.01). Switching was more common from ranibizumab (37 eyes, 23%) than from aflibercept (17 eyes, 11%; p=0.002).ConclusionVisual outcomes at 12 months in this direct comparison of ranibizumab and aflibercept for BRVO in real-world practice were generally good and similar for the 2 drugs, despite a greater effect of aflibercept on CST and time to first grading of inactivity.
Databáze: OpenAIRE
Externí odkaz: